Targeting tyrosine kinase receptors in hepatocellular carcinoma

Current Cancer Drug Targets

Volumn 13, Issue 3, 2013, Pages 300-312

  Muntané, Jordi ^a,c   De la Rosa, Angel J ^a   Docobo, Fernando ^a   García Carbonero, Rocío ^b   Padillo, Francisco J ^a,c  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Instituto de Biomedicina de Sevilla   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cancer; Cell death; Proliferation; Receptors; Tumor

Indexed keywords

ANGIOGENIC FACTOR; BRIVANIB; CEDIRANIB; DOVITINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR 2; FORETINIB; GEFITINIB; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; LAPATINIB; ORANTINIB; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; SOMATOMEDIN; SORAFENIB; STAT3 PROTEIN; SUNITINIB; TIVANTINIB; TRANSFORMING GROWTH FACTOR ALPHA; TYROSINE KINASE RECEPTOR; VANDETANIB; VASCULOTROPIN; VATALANIB;

ABDOMINAL PAIN; ANEMIA; ANGIOGENESIS; ANOREXIA; APOPTOSIS; BRAIN DISEASE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG STRUCTURE; FATIGUE; FEVER; GENE EXPRESSION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; EVIDENCE-BASED MEDICINE; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84876851311     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113139990075     Document Type: Review

References (117)

1. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55, 74-108.
2. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001, 94, 153-6.
3. El-Serag, H. B.; Rudolph, K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132, 2557-76.
4. Sangiovanni, A.; Del Ninno, E.; Fasani, P.; De Fazio, C.; Ronchi, G.; Romeo, R.; Morabito, A.; De Franchis, R.; Colombo, M. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004, 126, 1005-14.
5. Fattovich, G.; Stroffolini, T.; Zagni, I.; Donato, F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127, S35-S50.
6. Caldwell, S. H.; Crespo, D. M.; Kang, H. S.; Al-Osaimi, A. M. Obesity and hepatocellular carcinoma. Gastroenterology 2004, 127, S97-103.
7. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2012, 56, 908-943.
8. Colombo, M. Hepatocellular carcinoma. J. Hepatol. 1992, 15, 225-236.
9. Llovet, J. M.; Real, M. I.; Montana, X.; Planas, R.; Coll, S.; Aponte, J.; Ayuso, C.; Sala, M.; Muchart, J.; Sola, R.; Rodes, J.; Bruix, J. Barcelona Liver Cancer G. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359, 1734-1739.
10. Lo, C. M.; Ngan, H.; Tso, W. K.; Liu, C. L.; Lam, C. M.; Poon, R. T.; Fan, S. T.; Wong, J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35, 1164-1171.
11. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378-390.
12. Farazi, P. A.; DePinho, R. A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6, 674-687.
13. Simonetti, R. G.; Liberati, A.; Angiolini, C.; Pagliaro, L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann. Oncol. 1997, 8, 117-136.
14. Ng, I. O.; Liu, C. L.; Fan, S. T.; Ng, M. Expression of Pglycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am. J. Clin. Pathol. 2000, 113, 355-363.
15. Endicott, J. A.; Ling, V. The biochemistry of P-glycoproteinmediated multidrug resistance. Annu. Rev. Biochem. 1989, 58, 137-171.
16. Llovet, J. M.; Bruix, J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48, 1312-1327.
17. Villanueva, A.; Newell, P.; Chiang, D. Y.; Friedman, S. L.; Llovet, J. M. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 2007, 27, 55-76.
18. Avila, M. A.; Berasain, C.; Sangro, B.; Prieto, J. New therapies for hepatocellular carcinoma. Oncogene 2006, 25, 3866-3884.
19. Ivy, S. P.; Wick, J. Y.; Kaufman, B. M. An overview of smallmolecule inhibitors of VEGFR signaling. Nat. Rev. Clin. Oncol. 2009, 6, 569-579.
20. Dancey, J.; Sausville, E. A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2003, 2, 296-313.
21. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29, 15-18.
22. Shojaei, F.; Ferrara, N. Antiangiogenic therapy for cancer: an update. Cancer J. 2007, 13, 345-348.
23. Andrae, J.; Gallini, R.; Betsholtz, C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008, 22, 1276-1312.
24. Fojo, T.; Parkinson, D. R. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin. Cancer Res. 2010, 16, 5972-5980.
25. Huynh, H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem. Pharmacol. 2010, 80, 550-560.
26. Mise, M.; Arii, S.; Higashituji, H.; Furutani, M.; Niwano, M.; Harada, T.; Ishigami, S.; Toda, Y.; Nakayama, H.; Fukumoto, M.; Fujita, J.; Imamura, M. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996, 23, 455-464.
27. Chiang, D. Y.; Villanueva, A.; Hoshida, Y.; Peix, J.; Newell, P.; Minguez, B.; LeBlanc, A. C.; Donovan, D. J.; Thung, S. N.; Sole, M.; Tovar, V.; Alsinet, C.; Ramos, A. H.; Barretina, J.; Roayaie, S.; Schwartz, M.; Waxman, S.; Bruix, J.; Mazzaferro, V.; Ligon, A. H.; Najfeld, V.; Friedman, S. L.; Sellers, W. R.; Meyerson, M.; Llovet, J. M. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 2008, 68, 6779-6788.
28. Miura, H.; Miyazaki, T.; Kuroda, M.; Oka, T.; Machinami, R.; Kodama, T.; Shibuya, M.; Makuuchi, M.; Yazaki, Y.; Ohnishi, S. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J. Hepatol. 1997, 27, 854-861.
29. Chao, Y.; Li, C. P.; Chau, G. Y.; Chen, C. P.; King, K. L.; Lui, W. Y.; Yen, S. H.; Chang, F. Y.; Chan, W. K.; Lee, S. D. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann. Surg. Oncol. 2003, 10, 355-362.
30. Poon, R. T.; Ho, J. W.; Tong, C. S.; Lau, C.; Ng, I. O.; Fan, S. T. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 2004, 91, 1354-1360.
31. Zhang, T.; Sun, H. C.; Xu, Y.; Zhang, K. Z.; Wang, L.; Qin, L. X.; Wu, W. Z.; Liu, Y. K.; Ye, S. L.; Tang, Z. Y. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin. Cancer Res. 2005, 11, 8557-8563.
32. Ostman, A.; Heldin, C. H. PDGF receptors as targets in tumor treatment. Adv. Cancer Res. 2007, 97, 247-274.
33. Huynh, H.; Ngo, V. C.; Fargnoli, J.; Ayers, M.; Soo, K. C.; Koong, H. N.; Thng, C. H.; Ong, H. S.; Chung, A.; Chow, P.; Pollock, P.; Byron, S.; Tran, E. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer. Res. 2008, 14, 6146-6153.
34. Morelli, M. P.; Brown, A. M.; Pitts, T. M.; Tentler, J. J.; Ciardiello, F.; Ryan, A.; Jurgensmeier J. M.; Eckhardt, S. G. Targeting vascular endothelial growth factor receptor-1 and-3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Mol. Cancer Ther. 2009, 8, 2546-2558.
35. Tao, L. Y.; Liang, Y. J.; Wang, F.; Chen, L. M.; Yan, Y. Y.; Dai, C. L.; Fu, L. W. Cediranib (recentin, AZD2171) reverses ABCB1-and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother. Pharmacol. 2009, 64, 961-969.
36. Park, J. W.; Finn, R. S.; Kim, J. S.; Karwal, M.; Li, R. K.; Ismail, F.; Thomas, M.; Harris, R.; Baudelet, C.; Walters, I.; Raoul, J. L. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 2011, 17, 1973-1983.
37. Finn, R. S.; Kang, Y. K.; Mulcahy, M.; Polite, B. N.; Lim, H. Y.; Walters, I.; Baudelet, C.; Manekas, D.; Park, J. W. Phase II, openlabel study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 2012, 18, 2090-2098.
38. Villanueva, A.; Llovet, J. M. Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin. Cancer Res. 2012, 18, 1824-1826.
39. Drevs, J.; Siegert, P.; Medinger, M.; Mross, K.; Strecker, R.; Zirrgiebel, U.; Harder, J.; Blum, H; Robertson, J.; Jurgensmeier, J. M.; Puchalski, T. A.; Young, H.; Saunders, O.; Unger, C. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2007, 25, 3045-3054.
40. Alberts, S. R.; Fitch, T. R.; Kim, G. P.; Morlan, B. W.; Dakhil, S. R.; Gross, H. M.; Nair, S. Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial. Am. J. Clin. Oncol. 2012, 35, 329-333.
41. Kitamura, R.; Asanoma, H.; Nagayama, S.; Otagiri, M. Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1Hpyrrole-3-pr opanoic acid (TSU-68). Drug. Metab. Dispos. 2008, 36, 1003-1009.
42. Kanai, F.; Yoshida, H.; Tateishi, R.; Sato, S.; Kawabe, T.; Obi, S.; Kondo, Y.; Taniguchi, M.; Tagawa, K.; Ikeda, M.; Morizane, C.; Okusaka, T.; Arioka, H.; Shiina, S.; Omata, M. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 2011, 67, 315-324.
43. Bagi, C. M.; Gebhard, D. F.; Andresen, C. J. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 2012, 24, 563-574.
44. Huynh, H.; Ngo, V. C.; Choo, S. P.; Poon, D.; Koong, H. N.; Thng, C. H.; Toh, H. C.; Zheng, L.; Ong, L. C.; Jin, Y.; Song, I. C.; Chang, A. P.; Ong, H. S.; Chung, A. Y.; Chow, P. K.; Soo, K. C. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Curr. Cancer Drug Targets 2009, 9, 738-747.
45. Zhu, A. X.; Sahani, D. V.; Duda, D. G.; di Tomaso, E.; Ancukiewicz, M.; Catalano, O. A.; Sindhwani, V.; Blaszkowsky, L. S.; Yoon, S. S.; Lahdenranta, J.; Bhargava, P.; Meyerhardt, J.; Clark, J. W.; Kwak, E. L.; Hezel, A. F.; Miksad, R.; Abrams, T. A.; Enzinger, P. C.; Fuchs, C. S.; Ryan, D. P.; Jain, R. K. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 2009, 27, 3027-3035.
46. Faivre, S.; Raymond, E.; Boucher, E; Douillard, J.; Lim, H. Y.; Kim, J. S.; Zappa, M.; Lanzalone S.; Lin, X.; Deprimo, S.; Harmon, C.; Ruiz-Garcia, A.; Lechuga, M. J.; Cheng, A. L. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009, 10, 794-800.
47. Faivre, S. J.; Bouattour, M.; Dreyer, C.; Raymond, E. Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. J. Clin. Oncol. 2009, 27, e248-50, author reply e251-2.
48. Forner, A.; Llovet, J. M.; Bruix, J. Sunitinib and the benefits of a negative study. Lancet Oncol. 2009, 10, 743-744.
49. Huynh, H.; Chow, P. K.; Tai, W. M.; Choo, S. P.; Chung, A. Y.; Ong, H. S.; Soo, K. C.; Ong, R.; Linnartz, R.; Shi, M. M. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J. Hepatol. 2012, 56, 595-601.
50. Tai, W. T.; Cheng, A. L.; Shiau, C. W.; Liu, C. Y.; Ko, C. H.; Lin, M. W.; Chen, P. J.; Chen, K. F. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Mol. Cancer Ther. 2012, 11, 452-463.
51. Sarker, D.; Molife, R.; Evans, T. R.; Hardie, M.; Marriott, C.; Butzberger-Zimmerli, P.; Morrison, R.; Fox, J. A.; Heise, C.; Louie, S.; Aziz, N.; Garzon, F.; Michelson, G.; Judson, I. R.; Jadayel, D.; Braendle, E.; de Bono, J. S. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14, 2075-2081.
52. Liu, Y.; Poon, R. T.; Li, Q.; Kok, T. W.; Lau, C.; Fan, S. T. Both antiangiogenesis-and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2005, 65, 3691-3699.
53. Murakami, M.; Kobayashi, S.; Marubashi, S.; Tomimaru, Y.; Noda, T.; Wada, H.; Eguchi, H.; Takeda, Y.; Tanemura, M.; Umeshita, K.; Doki, Y.; Mori, M.; Nagano, H. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferonalpha/ 5-fluorouracil therapy for hepatocellular carcinoma cells. Ann. Surg. Oncol. 2011, 18, 589-596.
54. Yau, T.; Chan, P.; Pang, R.; Ng, K.; Fan, S. T.; Poon, R. T. Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. Cancer 2010, 116, 5022-5029.
55. Villanueva, A.; Hoshida, Y.; Battiston, C.; Tovar, V.; Sia, D.; Alsinet, C.; Cornella, H.; Liberzon, A.; Kobayashi, M.; Kumada, H.; Thung, S. N.; Bruix, J.; Newell, P.; April, C.; Fan, J. B.; Roayaie, S.; Mazzaferro, V.; Schwartz, M. E.; Llovet, J. M. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011, 140, 1501-1512 e2.
56. Liu, L.; Cao, Y.; Chen, C.; Zhang, X.; McNabola, A.; Wilkie, D.; Wilhelm, S.; Lynch, M.; Carter, C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66, 11851-11858.
57. Chen, K. F.; Tai, W. T.; Liu, T. H.; Huang, H. P.; Lin, Y. C.; Shiau, C. W.; Li, P. K.; Chen, P. J.; Cheng, A. L. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin. Cancer Res. 2010, 16, 5189-5199.
58. Tai, W. T.; Cheng, A. L.; Shiau, C. W.; Huang, H. P.; Huang, J. W.; Chen, P. J.; Chen, K. F. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J. Hepatol. 2011, 55, 1041-1048.
59. Newell, P.; Toffanin, S.; Villanueva, A.; Chiang, D. Y.; Minguez, B.; Cabellos, L.; Savic, R.; Hoshida, Y.; Lim, K. H.; Melgar-Lesmes, P.; Yea, S.; Peix, J.; Deniz, K.; Fiel, M. I.; Thung, S.; Alsinet, C.; Tovar, V.; Mazzaferro, V.; Bruix, J.; Roayaie, S.; Schwartz, M.; Friedman, S. L.; Llovet, J. M. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J. Hepatol. 2009, 51, 725-733.
60. Abou-Alfa, G. K.; Schwartz, L.; Ricci, S.; Amadori, D.; Santoro, A.; Figer, A.; De Greve, J.; Douillard, J. Y.; Lathia, C.; Schwartz, B.; Taylor, I.; Moscovici, M.; Saltz, L. B. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2006, 24, 4293-4300.
61. Casanovas, O.; Hicklin, D. J.; Bergers, G.; Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8, 299-309.
62. Sawey, E. T.; Chanrion, M.; Cai, C.; Wu, G.; Zhang, J.; Zender, L.; Zhao, A.; Busuttil, R. W.; Yee, H.; Stein, L.; French, D. M.; Finn, R. S.; Lowe, S. W.; Powers, S. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 2011, 19, 347-358.
63. Worns, M. A.; Schuchmann, M.; Duber, C.; Otto, G.; Galle, P. R.; Weinmann, A. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology 2010, 79, 85-92.
64. Wieduwilt, M. J.; Moasser, M. M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol. Life Sci. 2008, 65, 1566-1584.
65. Burgering, B. M.; Coffer, P. J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995, 376, 599-602.
66. Scaltriti, M.; Baselga, J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 2006, 12, 5268-5272.
67. Normanno, N.; De Luca, A.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M. R.; Carotenuto, A.; De Feo, G.; Caponigro, F.; Salomon, D. S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366, 2-16.
68. Su, M. C.; Hsu, C.; Kao, H. L.; Jeng, Y. M. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett. 2006, 235, 34-39.
69. Yeh, Y. C.; Tsai, J. F.; Chuang, L. Y.; Yeh, H. W.; Tsai, J. H.; Florine, D. L.; Tam, J. P. Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alphafetoprotein levels in patients with hepatocellular carcinoma. Cancer Res. 1987, 47, 896-901.
70. Feitelson, M. A.; Pan, J.; Lian, Z. Early molecular and genetic determinants of primary liver malignancy. Surg. Clin. North Am. 2004, 84, 339-354.
71. Castillo, J.; Erroba, E.; Perugorria, M. J.; Santamaria, M.; Lee, D. C.; Prieto, J.; Avila, M. A.; Berasain, C. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res. 2006, 66, 6129-6138.
72. Desbois-Mouthon, C.; Cacheux, W.; Blivet-Van Eggelpoel, M. J.; Barbu, V.; Fartoux, L.; Poupon, R.; Housset, C.; Rosmorduc, O. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int. J. Cancer 2006, 119, 2557-2566.
73. Hoshida, Y.; Villanueva, A.; Kobayashi, M.; Peix, J.; Chiang, D. Y.; Camargo, A.; Gupta, S.; Moore, J.; Wrobel, M. J.; Lerner, J.; Reich, M.; Chan, J. A.; Glickman, J. N.; Ikeda, K.; Hashimoto, M.; Watanabe, G.; Daidone, M. G.; Roayaie, S.; Schwartz, M.; Thung, S.; Salvesen, H. B.; Gabriel, S.; Mazzaferro, V.; Bruix, J.; Friedman, S. L.; Kumada, H.; Llovet, J. M.; Golub, T. R. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 1995-2004.
74. Ellouk-Achard, S.; Djenabi, S.; De Oliveira, G. A.; Desauty, G.; Duc, H. T.; Zohair, M.; Trojan, J.; Claude, J. R.; Sarasin, A.; Lafarge-Frayssinet, C. Induction of apoptosis in rat hepatocarcinoma cells by expression of IGF-I antisense c-DNA. J. Hepatol. 1998, 29, 807-818.
75. Hopfner, M.; Sutter, A. P.; Huether, A.; Schuppan, D.; Zeitz, M.; Scherubl, H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J. Hepatol. 2004, 41, 1008-1016.
76. Su, Q.; Liu, Y. F.; Zhang, J. F.; Zhang, S. X.; Li, D. F.; Yang, J. J. Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression. Hepatology 1994, 20, 788-799.
77. Boissan, M.; Beurel, E.; Wendum, D.; Rey, C.; Lecluse, Y.; Housset, C.; Lacombe, M. L.; Desbois-Mouthon, C. Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am. J. Pathol. 2005, 167, 869-877.
78. Huynh, H.; Chow, P. K.; Ooi, L. L.; Soo, K. C. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ. 2002, 13, 115-122.
79. Breuhahn, K.; Longerich, T.; Schirmacher, P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006, 25, 3787-3800.
80. Okano, J.; Matsumoto, K.; Nagahara, T.; Murawaki, Y. Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells. J. Gastroenterol. 2006, 41, 166-176.
81. Huether, A.; Hopfner, M.; Sutter, A. P.; Schuppan, D.; Scherubl, H. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J. Hepatol. 2005, 43, 661-669.
82. Huether, A.; Hopfner, M.; Sutter, A. P.; Baradari, V.; Schuppan, D.; Scherubl, H. Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J. Gastroenterol. 2006, 12, 5160-5167.
83. Matsuo, M.; Sakurai, H.; Saiki, I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol. Cancer Ther. 2003, 2, 557-561.
84. Zhu, B. D.; Yuan, S. J.; Zhao, Q. C.; Li, X.; Li, Y.; Lu, Q. Y. Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma. World J. Gastroenterol. 2005, 11, 1382-1386.
85. Ueda, S.; Basaki, Y.; Yoshie, M.; Ogawa, K.; Sakisaka, S.; Kuwano, M.; Ono, M. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer Res. 2006, 66, 5346-5353.
86. Philip, P.A.; Mahoney, M. R.; Allmer, C.; Thomas, J.; Pitot, H. C.; Kim, G.; Donehower, R. C.; Fitch, T.; Picus, J.; Erlichman, C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 2005, 23, 6657-6663.
87. Whittaker, S.; Marais, R.; Zhu, A. X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010, 29, 4989-5005.
88. Rusnak, D. W.; Lackey, K.; Affleck, K.; Wood, E. R.; Alligood, K. J.; Rhodes, N.; Keith, B. R.; Murray, D. M.; Knight, W. B.; Mullin, R. J.; Gilmer, T. M. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 2001, 1, 85-94.
89. El-Azab, A.S.; Al-Omar, M. A.; Abdel-Aziz, A. A.; Abdel-Aziz, N. I.; el-Sayed, M. A.; Aleisa, A. M.; Sayed-Ahmed, M. M.; Abdel-Hamide, S. G. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study. Eur. J. Med. Chem. 2010, 45, 4188-4198.
90. Bekaii-Saab, T.; Markowitz, J.; Prescott, N.; Sadee, W.; Heerema, N.; Wei, L.; Dai, Z.; Papp, A.; Campbell, A.; Culler, K.; Balint, C.; O'Neil, B.; Lee, R. M.; Zalupski, M.; Dancey, J.; Chen, H.; Grever, M.; Eng, C.; Villalona-Calero, M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin. Cancer Res. 2009, 15, 5895-5901.
91. Brave, S. R.; Odedra, R.; James, N. H.; Smith, N. R.; Marshall, G. B.; Acheson, K. L.; Baker, D.; Howard, Z.; Jackson, L.; Ratcliffe, K.; Wainwright, A.; Lovick, S. C.; Hickinson, D. M.; Wilkinson, R. W.; Barry, S. T.; Speake, G.; Ryan, A. J. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. Int. J. Oncol. 2011, 39, 271-278.
92. Inoue, K.; Torimura, T.; Nakamura, T.; Iwamoto, H.; Masuda, H.; Abe, M.; Hashimoto, O.; Koga, H.; Ueno, T.; Yano, H.; Sata, M. Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice. Clin. Cancer Res. 2012, 18, 3924-3933.
93. Hsu, C.; Yang, T. S.; Huo, T. I.; Hsieh, R. K.; Yu, C. W.; Hwang, W. S.; Hsieh, T. Y.; Huang, W. T.; Chao, Y.; Meng, R.; Cheng, A. L. Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebocontrolled study. J. Hepatol. 2012, 56, 1097-1103.
94. Gilmore, A. P.; Valentijn, A. J.; Wang, P.; Ranger, A. M.; Bundred, N.; O'Hare, M. J.; Wakeling, A.; Korsmeyer, S. J.; Streuli, C. H. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J. Biol. Chem. 2002, 277, 27643-27650.
95. Hopfner, M.; Huether, A.; Sutter, A. P.; Baradari, V.; Schuppan, D.; Scherubl, H. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem. Pharmacol. 2006, 71, 1435-1448.
96. Desbois-Mouthon, C.; Baron, A.; Blivet-Van Eggelpoel, M. J.; Fartoux, L.; Venot, C.; Bladt, F.; Housset, C.; Rosmorduc, O. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin. Cancer Res. 2009, 15, 5445-5456.
97. Ludovini, V.; Bellezza, G.; Pistola, L.; Bianconi, F.; Di Carlo, L.; Sidoni, A.; Semeraro, A.; Del Sordo, R.; Tofanetti, F. R.; Mameli, M. G.; Daddi, G.; Cavaliere, A.; Tonato, M.; Crino, L. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann. Oncol. 2009, 20, 842-849.
98. Choi, Y. J.; Rho, J. K.; Jeon, B. S.; Choi, S. J.; Park, S. C.; Lee, S. S.; Kim, H. R.; Kim, C. H.; Lee, J. C. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. Cancer Chemother. Pharmacol. 2010, 66, 381-388.
99. Efimova, E. A.; Glanemann, M.; Liu, L.; Schumacher, G.; Settmacher, U.; Jonas, S.; Langrehr, J. M.; Neuhaus, P.; Nussler, A. K. Effects of human hepatocyte growth factor on the proliferation of human hepatocytes and hepatocellular carcinoma cell lines. Eur. Surg. Res. 2004, 36, 300-307.
100. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G. F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4, 915-925.
101. Michieli, P.; Mazzone, M.; Basilico, C.; Cavassa, S.; Sottile, A.; Naldini, L.; Comoglio, P. M. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004, 6, 61-73.
102. Ding, S.; Merkulova-Rainon, T.; Han, Z. C.; Tobelem, G. HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 2003, 101, 4816-22.
103. Boix, L.; Rosa, J. L.; Ventura, F.; Castells, A.; Bruix, J.; Rodes, J.; Bartrons, R. c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology 1994, 19, 88-91.
104. Selden, C.; Farnaud, S.; Ding, S. F.; Habib, N.; Foster, C.; Hodgson, H. J. Expression of hepatocyte growth factor mRNA, and c-met mRNA (hepatocyte growth factor receptor) in human liver tumours. J. Hepatol. 1994, 21, 227-234.
105. Park, W. S.; Dong, S. M.; Kim, S. Y.; Na, E. Y.; Shin, M. S.; Pi, J. H.; Kim, B. J.; Bae, J. H.; Hong, Y. K.; Lee, K. S.; Lee, S. H.; Yoo, N. J.; Jang, J. J.; Pack, S.; Zhuang, Z.; Schmidt, L.; Zbar, B.; Lee, J. Y. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999, 59, 307-310.
106. Gao, J.; Inagaki, Y.; Song, P.; Qu, X.; Kokudo, N.; Tang, W. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. Pharmacol. Res. 2012, 65, 23-30.
107. Ivanovska, I.; Zhang, C.; Liu, A. M.; Wong, K. F.; Lee, N. P.; Lewis, P.; Philippar, U.; Bansal, D.; Buser, C.; Scott, M.; Mao, M.; Poon, R. T.; Fan, S. T.; Cleary, M. A.; Luk, J. M.; Dai, H. Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma. PLoS One 2011, 6, e24582.
108. Osada, S.; Kanematsu, M.; Imai, H.; Goshima, S. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology 2008, 55, 544-549.
109. Shojaei, F.; Lee, J. H.; Simmons, B. H.; Wong, A.; Esparza, C. O.; Plumlee, P. A.; Feng, J.; Stewart, A. E.; Hu-Lowe, D. D.; Christensen, J. G. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer. Res. 2010, 70, 10090-11100.
110. Salvi, A.; Arici, B.; Portolani, N.; Giulini, S. M.; De Petro, G.; Barlati, S. In vitro c-met inhibition by antisense RNA and plasmidbased RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int. J. Oncol. 2007, 31, 451-460.
111. You, H.; Ding, W.; Dang, H.; Jiang, Y.; Rountree, C. B. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 2011, 54, 879-889.
112. Inagaki, Y.; Qi, F.; Gao, J.; Qu, X.; Hasegawa, K.; Sugawara, Y.; Tang, W.; Kokudo, N. Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci. Trends. 2011, 5, 52-56.
113. Kaufmann, R.; Oettel, C.; Horn, A.; Halbhuber, K. J.; Eitner, A.; Krieg, R.; Katenkamp, K.; Henklein, P.; Westermann, M.; Bohmer, F. D.; Ramachandran, R.; Saifeddine, M.; Hollenberg, M. D.; Settmacher, U. Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion. Carcinogenesis 2009, 30, 1487-1496.
114. Qian, F.; Engst, S.; Yamaguchi, K.; Yu, P.; Won, K. A.; Mock, L.; Lou, T.; Tan, J.; Li, C.; Tam, D.; Lougheed, J.; Yakes, F. M.; Bentzien, F.; Xu, W.; Zaks, T.; Wooster, R.; Greshock, J.; Joly, A. H. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 2009, 69, 8009-8016.
115. Huynh, H.; Ong, R.; Soo, K. C. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis 2012, 15, 59-70.
116. Eder, J. P.; Shapiro, G. I.; Appleman, L. J.; Zhu, A. X.; Miles, D.; Keer, H.; Cancilla, B.; Chu, F.; Hitchcock-Bryan, S.; Sherman, L.; McCallum, S.; Heath, E. I.; Boerner, S. A.; LoRusso, P. M. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin. Cancer Res. 2010, 16, 3507-3516.
117. Frenette, C.; Gish, R. Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. World J. Gastroenterol. 2012, 18, 498-506.